ArticleChronic respiratory disease
Risk factors for mortality in Finnish bronchiectasis patients: A four-year study.
Article in Chronic respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundWe aimed to identify the risk factors associated with all-cause mortality in non-cystic fibrosis bronchiectasis (BE) patients in a Finnish cohort.MethodsIn this 4-years follow-up study, the data of non-cystic fibrosis adult BE patients were collected annually from medical records. Finnish translation of the disease-specific quality of life-bronchiectasis (QoL-B) questionnaire, the bronchiectasis severity index (BSI), FACED score, E-FACED score (exacerbations, (E), FEV1 (F), age (A), pulmonary bacterial colonization (C), number of lobes affected by BE (E), and dyspnoea (D), and modified Medical Research Council (mMRC) dyspnoea scale were used. Cox's regression analysis was used to evaluate factors with mortality.ResultsA total of 95 out of 205 adult non-cystic fibrosis BE patients were included and 79% of them were women with mean age of 69 years (SD ± 13). During the follow-up, eight patients died (8.4%). High scores of FACED (HR 1.9 CI 1.1-3.0), E-FACED (HR 1.5 CI 1.1-2.1) and mMRC (HR 3.2 CI 1.5-6.9) were increased the risk of mortality. The specific aetiology of BE, however, does not affect mortality. Low score of domains in QoL-B, physical (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.